IL-6-mediated inflammation correlates with debilitating cancer-related symptoms such as fatigue, thromboembolism, cachexia, and anemia [3], and IL-6 signaling activation correlates with lung cancer chemotherapy resistance [16,24]. Here, IL6 is linked to lung carcinoma.